Q1 Earnings Forecast for SNDX Issued By B. Riley

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) - Investment analysts at B. Riley issued their Q1 2025 EPS estimates for Syndax Pharmaceuticals in a research note issued to investors on Monday, March 3rd. B. Riley analyst K. Patel expects that the company will post earnings per share of ($1.11) for the quarter. The consensus estimate for Syndax Pharmaceuticals' current full-year earnings is ($3.72) per share. B. Riley also issued estimates for Syndax Pharmaceuticals' Q2 2025 earnings at ($1.11) EPS.

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last posted its quarterly earnings results on Monday, March 3rd. The company reported ($1.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by ($0.79). The firm had revenue of $7.68 million during the quarter, compared to analysts' expectations of $86.32 million.

SNDX has been the subject of several other research reports. HC Wainwright reissued a "buy" rating and set a $51.00 price target on shares of Syndax Pharmaceuticals in a research report on Tuesday, March 4th. StockNews.com cut Syndax Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Saturday, November 23rd. JPMorgan Chase & Co. upped their price target on Syndax Pharmaceuticals from $35.00 to $39.00 and gave the company an "overweight" rating in a report on Tuesday, March 4th. Citigroup reduced their price objective on Syndax Pharmaceuticals from $45.00 to $42.00 and set a "buy" rating for the company in a report on Tuesday, March 4th. Finally, Scotiabank lowered their target price on shares of Syndax Pharmaceuticals from $18.00 to $16.00 and set a "sector perform" rating on the stock in a research note on Wednesday, January 8th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and nine have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $36.00.

Remove Ads

Syndax Pharmaceuticals Trading Down 6.1 %

NASDAQ:SNDX traded down $0.87 on Wednesday, reaching $13.42. 3,422,059 shares of the stock traded hands, compared to its average volume of 2,354,926. The company's fifty day simple moving average is $14.33 and its 200 day simple moving average is $16.60. The company has a market capitalization of $1.15 billion, a price-to-earnings ratio of -3.70 and a beta of 0.92. Syndax Pharmaceuticals has a 12 month low of $12.06 and a 12 month high of $25.16.

Insider Buying and Selling

In related news, insider Neil Gallagher sold 4,618 shares of Syndax Pharmaceuticals stock in a transaction on Monday, February 10th. The stock was sold at an average price of $15.50, for a total transaction of $71,579.00. Following the transaction, the insider now directly owns 85,095 shares in the company, valued at approximately $1,318,972.50. The trade was a 5.15 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Michael A. Metzger sold 13,288 shares of the company's stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $15.50, for a total value of $205,964.00. Following the completion of the sale, the chief executive officer now owns 300,121 shares of the company's stock, valued at approximately $4,651,875.50. The trade was a 4.24 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 21,683 shares of company stock valued at $336,087. 4.10% of the stock is owned by insiders.

Institutional Trading of Syndax Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of SNDX. Assenagon Asset Management S.A. increased its stake in Syndax Pharmaceuticals by 343.0% in the 4th quarter. Assenagon Asset Management S.A. now owns 2,064,456 shares of the company's stock worth $27,292,000 after buying an additional 1,598,428 shares in the last quarter. Soleus Capital Management L.P. grew its position in shares of Syndax Pharmaceuticals by 128.4% during the fourth quarter. Soleus Capital Management L.P. now owns 2,492,000 shares of the company's stock worth $32,944,000 after purchasing an additional 1,401,016 shares in the last quarter. Octagon Capital Advisors LP bought a new stake in Syndax Pharmaceuticals during the 4th quarter valued at approximately $11,951,000. BNP PARIBAS ASSET MANAGEMENT Holding S.A. purchased a new position in Syndax Pharmaceuticals in the 3rd quarter worth approximately $15,165,000. Finally, Eventide Asset Management LLC purchased a new position in Syndax Pharmaceuticals in the 3rd quarter worth approximately $15,150,000.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).